Patrick Daly

DocwireNews

Researchers, led by Yuqing Song, sought to uncover potential risk factors driving progression of immune thrombocytopenia (ITP) to systemic lupus erythematosus (SLE) in pediatric Chinese patients. In the study&rsquo;s report, published in Annals of Hematology, the authors reported that &ldquo;older age and hypocomplementemia were potential risk factors for the development from ITP to SLE.&rdquo;The retrospective case-control study included a total of 50 patients with ITP that had progressed to SLE, and 100 control patients that had ITP without developing SLE. Uni- and multivariable logistic regression models were developed to identify the risk factors for disease progression.According to the report, the median time of development of ITP to SLE was 34.5 months (interquartile range [IQR]: 12.5&ndash;58.75). The authors identified that the antinuclear antibody (ANA) was significantly different between the groups in univariable analysis but the difference was not present in multivariable analysis (odds ratio = 4.50; 95% confidence interval [CI], 0.97&ndash;21.01). Additionally, &ldquo;age diagnosed ITP was positively associated with SLE (odds ratio [OR] = 1.07 every 5 years, 95% CI 1.01 to 1.15) with alert point at 8 years old (sensitivity 0.82, specificity 0.60),&rdquo; according to the authors. Lastly, a lower level of complement was also positively associated with SLE (odds ratio [OR] = 8.33; 95% CI, 1.62&ndash;42.91).Ultimately, the authors presented the risk factors for progression to SLE in pediatric patients with ITP identified by their statistical analysis. The authors advised a &ldquo;minimum 3-year of close follow-up for pediatric ITP patients &hellip; to monitor the risk for developing SLE.&rdquo;

Sara Nunnery, MD, MSCI

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

HER2 Breast Cancer

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

Latest News

Risk Factors for Progression of Immune Thrombocytopenia to Systemic Lupus Erythematosus

Researchers, led by Yuqing Song, sought to uncover potential risk factors driving progression of immune thrombocytopenia (ITP) to systemic lupus erythematosus (SLE) in ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe